Cargando…
Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients
This study determined the efficacy and safety of a modified FOLFOX regimen that improved patient convenience without compromising oxaliplatin dose intensity. A total of 62 patients with previously untreated metastatic colorectal cancer were enrolled to receive, entirely as outpatients, 2-weekly cycl...
Autores principales: | Goldstein, D, Mitchell, P, Michael, M, Beale, P, Friedlander, M, Zalcberg, J, White, S, Clarke, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361919/ https://www.ncbi.nlm.nih.gov/pubmed/15756253 http://dx.doi.org/10.1038/sj.bjc.6602426 |
Ejemplares similares
-
Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009) -
The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019) -
Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy
por: Lin, Gui-Nan, et al.
Publicado: (2016) -
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
por: Wang, Feng, et al.
Publicado: (2022) -
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)